Nuvalent reports $719.9M cash; launches 'OnTarget 2026' plan targeting first approval in 2026

Nuvalent, Inc.

Cash, cash equivalents and marketable securities of $719.9M as of Dec 31, 2023 (unaudited); expected to fund operations into 2027.
OnTarget 2026 plan aims for first potential approved product in 2026, with pivotal data from at least one lead program in 2025.
2024 milestones: advance Phase 2 ARROS-1 (NVL-520) and initiate Phase 2 ALKOVE-1 (NVL-655), launch front-line ALK strategy, start Phase 1 for HER2 program.
Interim data from ARROS-1 and ALKOVE-1 expected at medical meetings in 2024.
Company to present at J.P. Morgan Healthcare Conference on Jan 9, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.